NSD2 and breast cancer: NSD2-mediated metabolic reprogramming confers resistance to tamoxifen, an anti-estrogen [137], and treatment with DZNep, an indirect inhibitor of methyltransferases, induces NSD2 degradation, thus restoring tamoxifen sensitivity in breast cancer [155].